Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P4VX
|
|||
| Former ID |
DAP000058
|
|||
| Drug Name |
Terlipressin
|
|||
| Synonyms |
Glypressin; Lucassin; Terlipressina; Terlipressine; Terlipressinum; Glypressin (TN); HS-2028; Terlipressin [BAN:INN]; Terlipressina [INN-Spanish]; Terlipressine [INN-French]; Terlipressinum [INN-Latin]; N-(N-(N-Glycylglycyl)glycyl)-8-L-lysinevasopressin
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Approved | [1] | |
| Therapeutic Class |
Vasoconstrictor Agents
|
|||
| Company |
Ferring Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C52H74N16O15S2
|
|||
| Canonical SMILES |
C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N
|
|||
| InChI |
1S/C52H74N16O15S2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80)/t31-,32-,33-,34-,35-,36-,37-,38-/m0/s1
|
|||
| InChIKey |
BENFXAYNYRLAIU-QSVFAHTRSA-N
|
|||
| CAS Number |
CAS 14636-12-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
8195004, 14792660, 43128306, 46504626, 47208323, 50062330, 50887237, 57318514, 92098554, 93815097, 104352042, 117569638, 124896640, 126667357, 134337386, 135030842, 135752714, 137006272, 144206925, 152134056, 160965815, 162174262, 163319696, 164814212, 180372198, 184545337, 187072154, 223659635, 226411668, 252218927, 252359163
|
|||
| ChEBI ID |
CHEBI:135905
|
|||
| ADReCS Drug ID | BADD_D02167 | |||
| SuperDrug ATC ID |
H01BA04
|
|||
| SuperDrug CAS ID |
cas=014636125
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vasopressin V1a receptor (V1AR) | Target Info | Stimulator | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| Reactome | Vasopressin-like receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome. Expert Rev Gastroenterol Hepatol. 2007 Dec;1(2):207-17. | |||
| REF 2 | Investigational vasopressin receptor modulators in the pipeline. Expert Opin Investig Drugs. 2009 Aug;18(8):1119-31. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.